Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<
Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F
Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky
Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future.